Get started
AIM IMMUNOTECH INC COM USD0.001AIM IMMUNOTECH INC COM USD0.001AIM IMMUNOTECH INC COM USD0.001

AIM IMMUNOTECH INC COM USD0.001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0A4Y trade ideas

AIM 1W Final Edit Wave (4) (A)(B)(C) CorrectiveTest AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
AMEX:AIMLong
by TheCryptoChartWhisperer
AIM Aim Immuno - Top pick for at least 500% plus gain Based on recent data and the indications , safety data (already used in humans) and a need by various communities such as people afflicted with ME this should be the number one meme stock for getting people help while sticking it to the naked shorts. Insiders buying and with indications and data it should already be there. The market is currently subscribing only a $50mm value to this company if you take out over 1.00 per share in cash and yet their technology is showing promise in multiple areas. Lesser companies with 1 drug for one indication trade at $500mm mkt cap plus. This company had multiple hits in various indications each with broad market potential. Pancreatic and other Cancers / ME / Longhaulers / universal vaccine / alzheimers recent patent - the only reason why this isn't at $10.00 plus is the amount of naked shorting going on imho. If it get through 4.50 it flies just like $gme $amc etc. . Insiders buying and institutional ownership is increasing while the company has been quite in talking about the potential. The independent science reports speak louder than the company but not geared at Wall Street.
AMEX:AIMLong
by Hatchetaxe
AIM; Small Chart Analysis, Possible Cup and Handle formingDISCLAIMER This is in no way, shape or form, fluid and function, an analytical, qualitative or intelligent compte rendu. There is absolutely no financial advice here because the only financial advice I can give is to research, research, and research. The purpose of this analysis is to serve as an example of a small chart analysis. It looks like the current Elliot wave series is ending with a considerable amount of condensing in the current channel. The failure to get back to previous highs for so long has caused a turnover in investors and a possible placement to the backburner as a long trade. Meanwhile, AIM has had some minor news that could have sparked some minor volume and price increases on their own, but instead resulted in nothing. It is possible an analyst comes out with a revised price target soon after AIMs recent conferences, etc., that could propel it back to the ~$6/ line. It is also possible that the momentum is not enough as there has been so little interest and volume with AIM, and investors pull out with some profits and head for greener pastures. Stay vigilant, set limits and stops and have an exit plan. Good luck y'all. For a more thorough analysis on AIM, see
AMEX:AIMLong
by DoctorFaustus
AIM for the Sky*! Mileage may vary.Hello, take a seat and enjoy my basic analysis of AIM. I am not an analyst, of finances or anything else, just a dude saying friendly dude things. I could be the dude that everyone is friends with at the office, or I could be your crazy QAnon neighbour with a Ron Paul sign out front. Please do not trust anything I write without double checking and doing your own research as well! I will always put links to my sources for various things, but until I have enough rep I cannot. I will go back and fix these when I can! Science and Drug Development/Pipeline I always start with this, because if you don't have science on your side, then you aren't going to have the FDA on your side. Also I do science, so it's the best way for me to look at the company. AIM's science is simple, and not done by them. AIM is a clinical trial and manufacturing company, not a pharmaceutical. They have 2 drugs, first and most important one is Ampligen, second is Alferon N. Ampligen is Rintatolimod, which is a small double stranded RNA mismatch molecule. We all have DNA, and that DNA is double stranded. The DNA is used as a blueprint to make RNA, which will get used as a blueprint to make proteins, but RNA is never double-stranded, and when it is, it is taken care of immediately via several amazing pathways. Having double stranded RNA in your cell is going to set off alarms in that cell, forcing a response by that cell to check itself, and either wreck itself, or keep on living. This response also sends out various other signals that kind of tidy up the cell, slow it down and just make sure everything is working ok. Turns out doing this in most diseases is a good thing, who would've thought! The mechanism of action for Ampligen is to initiate an immune response, and let the cell fix itself, or kill itself. If it sounds vague, that's because it is. We know point A and point B, but we really don't know which path we are taking, how many paths and what other points we hit along the way. Going over some research articles on pubmed, it seems like rintatolimod is solid, it gets a lot done in a lot of cellular assays, has some clean pathway work, all that. I just wish any other company would be bringing it to market. It is being used in clinical trials as a combinatorial, which is a smart move because everyone loves combining drugs. In all seriousness, this is a unique innate immune system pathway, where targeting with PD-L1 and other chemotherapeutics at the same time might just be the magic trick. Think of it like the monster in a horror movie, you shoot it, chop off its head, whatever. Do it again, and again and again, don't wait to find out that it can grow back its arms. Just keep swinging. The second drug is Alferon N, and I don't have much to say about it. Its an interferon, its been tried in a ton of clinical trials, its super promising, just never works. Maybe they finally figured it out, I just don't believe that. The Company and the Team Wow, its ****ing nothing. No, really, go to their site and check it out, it's no one. The whole thing is oddly pathetic, I don't know if a competent soul works in any capacity there, or if they too just gave up. That is all super harsh, I am sure that is not the case, but I hate companies in medicine with no scientist, anywhere. If you click on the Partnering tab on their main site, you can find an email to literally just partner with them, because they either have no ability or have failed to do any meaningful partnerships themselves. The company is a sales company, trying to sell itself. And god do I hope anyone buys. The truth is, the patents are probably worth 100Mil easy, you can shutter everyone at the company, outsource manufacturing to anywhere else or build it into existing manufacturing space. The Fundamentals Tiny 90Mil market cap 40 Mil outstanding shares 7.7% institutional ownership, all of which increased in 12/31/20. (I wouldn't be surprised if this last correction was one pulling out with another buying in, just a normal change of hands) No debt, 40M in cash (as of last filing) No 13F/Gs, so no one is a majority owner. Possible Catalysts Someone buys them out Someone files a 13F and then buys them out They get a new CEO, who then sells the patent to anyone else and AIM becomes a holding company for the ampligen patent, with employee count of 1. For real: They are presenting at the Virtual Investor Summit March 24. If they build up some talk, and something nice gets published, they could see a good jump back. Conclusion If I were a bettin' man, I would say they can get a good cup and handle back to 4, or we could see some bigger impulse waves to 7 to form a long ass cup there. I don't trust a ton of investors to do a ton of work on research, so I can see them going forward quite a bit, but I have no problem jumping off myself. That's it, my brain is fried and I don't have anything else to say for now. Please let me know your thoughts, if you want to see anything else included in these, peace. Do your own research, I don't know anything.
AMEX:AIMLong
by DoctorFaustus
AIM: Greatest thing since sliced bread 🍞🔪Peaks are getting lower while troughs are getting higher in the duration of 5 days. You won't get a more obvious pennant than this. Now what makes this pennant bullish ? Well if we look at the Weekly log scale, we can see a clear case of a cup and handle, and we're almost done with the handle :) If we look at the same chart, we can see it broke a 5 year long trend line that has been perfectly touched COUNTLESS times by the weekly candle at close. Now what makes this "trend reversal not just another exhaustion like the previous one? Because the volume is INSANE with how little the price is moving right now. This trend GOT JUICE. So now do you understand why this simple pennant is so bullish? It's the culmination of so many bullish signals that makes this consolidation pattern so potent. As with all technical analysis there are no certainties, only probabilities. So don't go above your personal risk limit 📉. Anyways have fun trading, bye :)
AMEX:AIMLong
by Gurrel
$AIM is gonna fall todayPupm&Dump trading strategy idea. $AIM is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,49; stop-loss — $2,77; take-profit — $1,93; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
AMEX:AIMShort
by KozakHlib
AIMAIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen. Many survivors of the first SARS-CoV-1 epidemic in 2003 continued to report classic chronic fatigue-like symptoms after recovering from the acute illness. In fact, approximately 27% of survivors met the CDC criteria for chronic fatigue syndrome. There is now increasing evidence that patients with COVID-19 — the disease caused by SARS-CoV-2 — can develop a similar, ME/CFS-like illness. “With millions of U.S. cases of COVID-19 already on record we can expect a tidal wave of new U.S. cases of COVID-19 sufferers who will exhibit serious chronic fatigue-like symptoms. In addition, unpublished data from AIM indicates that ME/CFS patients respond better to Ampligen the earlier they receive the drug, so enrolling ‘Long Haulers’ earlier in their diagnosis could potentially benefit these patients while also providing valuable information for all ME/CFS patients.” An idea only not professional advice!
AMEX:AIMLong
by pureplanet
AIM - Float lock through 3 today gap tomm this is just the beginning folks, co. should be valued around $500mm = $13.00 and even then I would hold for everything they have going on... the person on their Special Advisory Board is a rockstar - bascially founded Amgen and their also working with Asagawa head of NIID WHO who loves Ampligen and is working with it right now... safe profile, let along all the work going on with CFS - watch the movie Forgotten Plague on Amazon - their stuff works with CFS if only Trump woke up to this.
AMEX:AIMLong
by Hatchetaxe
AIM - NIID currently testing it and safe - COVID / CANCER / CFS CHECK Ampligen has been used in humans for years for CFS - very similar to Long Haul Covid CHECK - Industry renown thought leader who is Director of the WHO has been working on Ampligen through Japan NIID CHECK - Roswell and other top cancer researchers have been ramping up testing of Ampligen CHECK - company has about $1.40 in net cash and restructured in 2016 CHECK - Neal Burnette godfather of vaccines is on Ampligens board as of 2016 CHECK - Ampligen is a TLR3 agonist which decreased viral yields in Sars and now might work as a intranasal prophylaxis UNCHECK - valuation of co. is less than $50mm does not compute give safety history and multiple at bats in cancer covid and CFS
AMEX:AIMLong
by Hatchetaxe
1